SELLAS Life Sciences Group, Inc. Accumulated Other Comprehensive Income
SELLAS Life Sciences Group, Inc. (SLS) had Accumulated Other Comprehensive Income of $0 as of 2013-12-31, per its 10-K filed 2014-03-17.
Discontinued › Balance Sheet › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2014-03-17
- 2013-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $0.00.
- 2013-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $1.72M.
- 2013-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $3.51M.
- 2013-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $5.89M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-17 |
| 2013-09-30 | $1.72M 10-Q/A · filed 2013-11-07 |
| 2013-06-30 | $3.51M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $5.89M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $1.63M 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |